Figure 2 | Scientific Reports

Figure 2

From: Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis

Figure 2The alternative text for this image may have been generated using AI.

Latent trajectories of response to Tocilizumab measured by DAS28. (A) All patient trajectories of DAS28 in response to Tocilizumab anti-IL6 treatment, with three identified latent trajectories of DAS28 in response to Tocilizumab over a 52-week clinical trial (B) mean trajectory for each identified latent class from baseline to week 52.

Back to article page